Retinitis pigmentosa is a kind of cortex on retinal pigment degeneration, chronic, progressive visual function, genetic, nutrition is not virtuous, retinal degenerative eye disease, the disease involving the eyes, men more than women, more incidence of 10 to 20 years old, a few people with the disease in the home, the faster progress in the earlier onset, curative effect is poorer, old age comes on slowly.
麻豆原创 Analysis and Insights: Global Retinitis Pigmentosa (Retinitis) 麻豆原创
The global Retinitis Pigmentosa (Retinitis) market is projected to grow from US$ million in 2024 to US$ million by 2030, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The US & Canada market for Retinitis Pigmentosa (Retinitis) is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
The China market for Retinitis Pigmentosa (Retinitis) is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
The Europe market for Retinitis Pigmentosa (Retinitis) is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
The global key companies of Retinitis Pigmentosa (Retinitis) include Sanofi, Amgen, Amarantus Bioscience Holdings, Acucela, Applied Genetic Technologies Corp, Asklepios BioPharmaceutical, Astellas Pharma, Caladrius Biosciences and Dompe Farmaceutici SpA, etc. In 2023, the global top five players had a share approximately % in terms of revenue.
Retinitis Pigmentosa (Retinitis) is widely used in various fields, such as Hospitals, Eye Clinics and Other,, etc. Hospitals provides greatest supports to the Retinitis Pigmentosa (Retinitis) industry development. In 2023, global % revenue of Retinitis Pigmentosa (Retinitis) went into Hospitals filed and the proportion will reach to % in 2030.
Report Covers:
This report presents an overview of global market for Retinitis Pigmentosa (Retinitis) market size. Analyses of the global market trends, with historic market revenue data for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030.
This report researches the key producers of Retinitis Pigmentosa (Retinitis), also provides the revenue of main regions and countries. Highlights of the upcoming market potential for Retinitis Pigmentosa (Retinitis), and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Retinitis Pigmentosa (Retinitis) revenue, market share and industry ranking of main companies, data from 2019 to 2024. Identification of the major stakeholders in the global Retinitis Pigmentosa (Retinitis) market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2019 to 2030. Evaluation and forecast the market size for Retinitis Pigmentosa (Retinitis) revenue, projected growth trends, production technology, application and end-user industry.
麻豆原创 Segmentation
By Company
Sanofi
Amgen
Amarantus Bioscience Holdings
Acucela
Applied Genetic Technologies Corp
Asklepios BioPharmaceutical
Astellas Pharma
Caladrius Biosciences
Dompe Farmaceutici SpA
Dormant Projects
GenSight Biologics SA
Grupo Ferrer Internacional SA
ID Pharma
InFlectis BioScience
Ionis Pharmaceuticals
Mimetogen Pharmaceuticals
M's Science Corp
Nanovector srl
Novartis AG
Novelion Therapeutics
ProQR Therapeutics
ReNeuron Group Plc
SanBio
Shire (Takeda Pharmaceutical)
Spark Therapeutics
Sun Pharma Advanced Research Company
Segment by Type
General Treatment
Traditional Chinese Medicine
Gene Therapy
The Surgical Treatment
Other
Segment by Application
Hospitals
Eye Clinics
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Revenue of Retinitis Pigmentosa (Retinitis) in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Retinitis Pigmentosa (Retinitis) companies鈥� competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America (US & Canada) by Type, by Application and by country, revenue for each segment.
Chapter 7: Europe by Type, by Application and by country, revenue for each segment.
Chapter 8: China by Type, and by Application, revenue for each segment.
Chapter 9: Asia (excluding China) by Type, by Application and by region, revenue for each segment.
Chapter 10: Middle East, Africa, and Latin America by Type, by Application and by country, revenue for each segment.
Chapter 11: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Retinitis Pigmentosa (Retinitis) revenue, gross margin, and recent development, etc.
Chapter 12: Analyst's Viewpoints/Conclusions
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Report Overview
1.1 Study Scope
1.2 麻豆原创 Analysis by Type
1.2.1 Global Retinitis Pigmentosa (Retinitis) 麻豆原创 Size Growth Rate by Type, 2019 VS 2023 VS 2030
1.2.2 General Treatment
1.2.3 Traditional Chinese Medicine
1.2.4 Gene Therapy
1.2.5 The Surgical Treatment
1.2.6 Other
1.3 麻豆原创 by Application
1.3.1 Global Retinitis Pigmentosa (Retinitis) 麻豆原创 Size Growth Rate by Application, 2019 VS 2023 VS 2030
1.3.2 Hospitals
1.3.3 Eye Clinics
1.3.4 Other
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Retinitis Pigmentosa (Retinitis) 麻豆原创 Perspective (2019-2030)
2.2 Global Retinitis Pigmentosa (Retinitis) Growth Trends by Region
2.2.1 Retinitis Pigmentosa (Retinitis) 麻豆原创 Size by Region: 2019 VS 2023 VS 2030
2.2.2 Retinitis Pigmentosa (Retinitis) Historic 麻豆原创 Size by Region (2019-2024)
2.2.3 Retinitis Pigmentosa (Retinitis) Forecasted 麻豆原创 Size by Region (2025-2030)
2.3 Retinitis Pigmentosa (Retinitis) 麻豆原创 Dynamics
2.3.1 Retinitis Pigmentosa (Retinitis) Industry Trends
2.3.2 Retinitis Pigmentosa (Retinitis) 麻豆原创 Drivers
2.3.3 Retinitis Pigmentosa (Retinitis) 麻豆原创 Challenges
2.3.4 Retinitis Pigmentosa (Retinitis) 麻豆原创 Restraints
3 Competition Landscape by Key Players
3.1 Global Revenue Retinitis Pigmentosa (Retinitis) by Players
3.1.1 Global Retinitis Pigmentosa (Retinitis) Revenue by Players (2019-2024)
3.1.2 Global Retinitis Pigmentosa (Retinitis) Revenue 麻豆原创 Share by Players (2019-2024)
3.2 Global Retinitis Pigmentosa (Retinitis) 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players of Retinitis Pigmentosa (Retinitis), Ranking by Revenue, 2022 VS 2023 VS 2024
3.4 Global Retinitis Pigmentosa (Retinitis) 麻豆原创 Concentration Ratio
3.4.1 Global Retinitis Pigmentosa (Retinitis) 麻豆原创 Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Retinitis Pigmentosa (Retinitis) Revenue in 2023
3.5 Global Key Players of Retinitis Pigmentosa (Retinitis) Head office and Area Served
3.6 Global Key Players of Retinitis Pigmentosa (Retinitis), Product and Application
3.7 Global Key Players of Retinitis Pigmentosa (Retinitis), Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Retinitis Pigmentosa (Retinitis) Breakdown Data by Type
4.1 Global Retinitis Pigmentosa (Retinitis) Historic 麻豆原创 Size by Type (2019-2024)
4.2 Global Retinitis Pigmentosa (Retinitis) Forecasted 麻豆原创 Size by Type (2025-2030)
5 Retinitis Pigmentosa (Retinitis) Breakdown Data by Application
5.1 Global Retinitis Pigmentosa (Retinitis) Historic 麻豆原创 Size by Application (2019-2024)
5.2 Global Retinitis Pigmentosa (Retinitis) Forecasted 麻豆原创 Size by Application (2025-2030)
6 North America
6.1 North America Retinitis Pigmentosa (Retinitis) 麻豆原创 Size (2019-2030)
6.2 North America Retinitis Pigmentosa (Retinitis) 麻豆原创 Size by Type
6.2.1 North America Retinitis Pigmentosa (Retinitis) 麻豆原创 Size by Type (2019-2024)
6.2.2 North America Retinitis Pigmentosa (Retinitis) 麻豆原创 Size by Type (2025-2030)
6.2.3 North America Retinitis Pigmentosa (Retinitis) 麻豆原创 Share by Type (2019-2030)
6.3 North America Retinitis Pigmentosa (Retinitis) 麻豆原创 Size by Application
6.3.1 North America Retinitis Pigmentosa (Retinitis) 麻豆原创 Size by Application (2019-2024)
6.3.2 North America Retinitis Pigmentosa (Retinitis) 麻豆原创 Size by Application (2025-2030)
6.3.3 North America Retinitis Pigmentosa (Retinitis) 麻豆原创 Share by Application (2019-2030)
6.4 North America Retinitis Pigmentosa (Retinitis) 麻豆原创 Size by Country
6.4.1 North America Retinitis Pigmentosa (Retinitis) 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
6.4.2 North America Retinitis Pigmentosa (Retinitis) 麻豆原创 Size by Country (2019-2024)
6.4.3 North America Retinitis Pigmentosa (Retinitis) 麻豆原创 Size by Country (2025-2030)
6.4.4 U.S.
6.4.5 Canada
7 Europe
7.1 Europe Retinitis Pigmentosa (Retinitis) 麻豆原创 Size (2019-2030)
7.2 Europe Retinitis Pigmentosa (Retinitis) 麻豆原创 Size by Type
7.2.1 Europe Retinitis Pigmentosa (Retinitis) 麻豆原创 Size by Type (2019-2024)
7.2.2 Europe Retinitis Pigmentosa (Retinitis) 麻豆原创 Size by Type (2025-2030)
7.2.3 Europe Retinitis Pigmentosa (Retinitis) 麻豆原创 Share by Type (2019-2030)
7.3 Europe Retinitis Pigmentosa (Retinitis) 麻豆原创 Size by Application
7.3.1 Europe Retinitis Pigmentosa (Retinitis) 麻豆原创 Size by Application (2019-2024)
7.3.2 Europe Retinitis Pigmentosa (Retinitis) 麻豆原创 Size by Application (2025-2030)
7.3.3 Europe Retinitis Pigmentosa (Retinitis) 麻豆原创 Share by Application (2019-2030)
7.4 Europe Retinitis Pigmentosa (Retinitis) 麻豆原创 Size by Country
7.4.1 Europe Retinitis Pigmentosa (Retinitis) 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
7.4.2 Europe Retinitis Pigmentosa (Retinitis) 麻豆原创 Size by Country (2019-2024)
7.4.3 Europe Retinitis Pigmentosa (Retinitis) 麻豆原创 Size by Country (2025-2030)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 China
8.1 China Retinitis Pigmentosa (Retinitis) 麻豆原创 Size (2019-2030)
8.2 China Retinitis Pigmentosa (Retinitis) 麻豆原创 Size by Type
8.2.1 China Retinitis Pigmentosa (Retinitis) 麻豆原创 Size by Type (2019-2024)
8.2.2 China Retinitis Pigmentosa (Retinitis) 麻豆原创 Size by Type (2025-2030)
8.2.3 China Retinitis Pigmentosa (Retinitis) 麻豆原创 Share by Type (2019-2030)
8.3 China Retinitis Pigmentosa (Retinitis) 麻豆原创 Size by Application
8.3.1 China Retinitis Pigmentosa (Retinitis) 麻豆原创 Size by Application (2019-2024)
8.3.2 China Retinitis Pigmentosa (Retinitis) 麻豆原创 Size by Application (2025-2030)
8.3.3 China Retinitis Pigmentosa (Retinitis) 麻豆原创 Share by Application (2019-2030)
9 Asia (excluding China)
9.1 Asia Retinitis Pigmentosa (Retinitis) 麻豆原创 Size (2019-2030)
9.2 Asia Retinitis Pigmentosa (Retinitis) 麻豆原创 Size by Type
9.2.1 Asia Retinitis Pigmentosa (Retinitis) 麻豆原创 Size by Type (2019-2024)
9.2.2 Asia Retinitis Pigmentosa (Retinitis) 麻豆原创 Size by Type (2025-2030)
9.2.3 Asia Retinitis Pigmentosa (Retinitis) 麻豆原创 Share by Type (2019-2030)
9.3 Asia Retinitis Pigmentosa (Retinitis) 麻豆原创 Size by Application
9.3.1 Asia Retinitis Pigmentosa (Retinitis) 麻豆原创 Size by Application (2019-2024)
9.3.2 Asia Retinitis Pigmentosa (Retinitis) 麻豆原创 Size by Application (2025-2030)
9.3.3 Asia Retinitis Pigmentosa (Retinitis) 麻豆原创 Share by Application (2019-2030)
9.4 Asia Retinitis Pigmentosa (Retinitis) 麻豆原创 Size by Region
9.4.1 Asia Retinitis Pigmentosa (Retinitis) 麻豆原创 Size by Region: 2019 VS 2023 VS 2030
9.4.2 Asia Retinitis Pigmentosa (Retinitis) 麻豆原创 Size by Region (2019-2024)
9.4.3 Asia Retinitis Pigmentosa (Retinitis) 麻豆原创 Size by Region (2025-2030)
9.4.4 Japan
9.4.5 South Korea
9.4.6 China Taiwan
9.4.7 Southeast Asia
9.4.8 India
9.4.9 Australia
10 Middle East, Africa, and Latin America
10.1 Middle East, Africa, and Latin America Retinitis Pigmentosa (Retinitis) 麻豆原创 Size (2019-2030)
10.2 Middle East, Africa, and Latin America Retinitis Pigmentosa (Retinitis) 麻豆原创 Size by Type
10.2.1 Middle East, Africa, and Latin America Retinitis Pigmentosa (Retinitis) 麻豆原创 Size by Type (2019-2024)
10.2.2 Middle East, Africa, and Latin America Retinitis Pigmentosa (Retinitis) 麻豆原创 Size by Type (2025-2030)
10.2.3 Middle East, Africa, and Latin America Retinitis Pigmentosa (Retinitis) 麻豆原创 Share by Type (2019-2030)
10.3 Middle East, Africa, and Latin America Retinitis Pigmentosa (Retinitis) 麻豆原创 Size by Application
10.3.1 Middle East, Africa, and Latin America Retinitis Pigmentosa (Retinitis) 麻豆原创 Size by Application (2019-2024)
10.3.2 Middle East, Africa, and Latin America Retinitis Pigmentosa (Retinitis) 麻豆原创 Size by Application (2025-2030)
10.3.3 Middle East, Africa, and Latin America Retinitis Pigmentosa (Retinitis) 麻豆原创 Share by Application (2019-2030)
10.4 Middle East, Africa, and Latin America Retinitis Pigmentosa (Retinitis) 麻豆原创 Size by Country
10.4.1 Middle East, Africa, and Latin America Retinitis Pigmentosa (Retinitis) 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
10.4.2 Middle East, Africa, and Latin America Retinitis Pigmentosa (Retinitis) 麻豆原创 Size by Country (2019-2024)
10.4.3 Middle East, Africa, and Latin America Retinitis Pigmentosa (Retinitis) 麻豆原创 Size by Country (2025-2030)
10.4.4 Brazil
10.4.5 Mexico
10.4.6 Turkey
10.4.7 Saudi Arabia
10.4.8 Israel
10.4.9 GCC Countries
11 Key Players Profiles
11.1 Sanofi
11.1.1 Sanofi Company Details
11.1.2 Sanofi Business Overview
11.1.3 Sanofi Retinitis Pigmentosa (Retinitis) Introduction
11.1.4 Sanofi Revenue in Retinitis Pigmentosa (Retinitis) Business (2019-2024)
11.1.5 Sanofi Recent Developments
11.2 Amgen
11.2.1 Amgen Company Details
11.2.2 Amgen Business Overview
11.2.3 Amgen Retinitis Pigmentosa (Retinitis) Introduction
11.2.4 Amgen Revenue in Retinitis Pigmentosa (Retinitis) Business (2019-2024)
11.2.5 Amgen Recent Developments
11.3 Amarantus Bioscience Holdings
11.3.1 Amarantus Bioscience Holdings Company Details
11.3.2 Amarantus Bioscience Holdings Business Overview
11.3.3 Amarantus Bioscience Holdings Retinitis Pigmentosa (Retinitis) Introduction
11.3.4 Amarantus Bioscience Holdings Revenue in Retinitis Pigmentosa (Retinitis) Business (2019-2024)
11.3.5 Amarantus Bioscience Holdings Recent Developments
11.4 Acucela
11.4.1 Acucela Company Details
11.4.2 Acucela Business Overview
11.4.3 Acucela Retinitis Pigmentosa (Retinitis) Introduction
11.4.4 Acucela Revenue in Retinitis Pigmentosa (Retinitis) Business (2019-2024)
11.4.5 Acucela Recent Developments
11.5 Applied Genetic Technologies Corp
11.5.1 Applied Genetic Technologies Corp Company Details
11.5.2 Applied Genetic Technologies Corp Business Overview
11.5.3 Applied Genetic Technologies Corp Retinitis Pigmentosa (Retinitis) Introduction
11.5.4 Applied Genetic Technologies Corp Revenue in Retinitis Pigmentosa (Retinitis) Business (2019-2024)
11.5.5 Applied Genetic Technologies Corp Recent Developments
11.6 Asklepios BioPharmaceutical
11.6.1 Asklepios BioPharmaceutical Company Details
11.6.2 Asklepios BioPharmaceutical Business Overview
11.6.3 Asklepios BioPharmaceutical Retinitis Pigmentosa (Retinitis) Introduction
11.6.4 Asklepios BioPharmaceutical Revenue in Retinitis Pigmentosa (Retinitis) Business (2019-2024)
11.6.5 Asklepios BioPharmaceutical Recent Developments
11.7 Astellas Pharma
11.7.1 Astellas Pharma Company Details
11.7.2 Astellas Pharma Business Overview
11.7.3 Astellas Pharma Retinitis Pigmentosa (Retinitis) Introduction
11.7.4 Astellas Pharma Revenue in Retinitis Pigmentosa (Retinitis) Business (2019-2024)
11.7.5 Astellas Pharma Recent Developments
11.8 Caladrius Biosciences
11.8.1 Caladrius Biosciences Company Details
11.8.2 Caladrius Biosciences Business Overview
11.8.3 Caladrius Biosciences Retinitis Pigmentosa (Retinitis) Introduction
11.8.4 Caladrius Biosciences Revenue in Retinitis Pigmentosa (Retinitis) Business (2019-2024)
11.8.5 Caladrius Biosciences Recent Developments
11.9 Dompe Farmaceutici SpA
11.9.1 Dompe Farmaceutici SpA Company Details
11.9.2 Dompe Farmaceutici SpA Business Overview
11.9.3 Dompe Farmaceutici SpA Retinitis Pigmentosa (Retinitis) Introduction
11.9.4 Dompe Farmaceutici SpA Revenue in Retinitis Pigmentosa (Retinitis) Business (2019-2024)
11.9.5 Dompe Farmaceutici SpA Recent Developments
11.10 Dormant Projects
11.10.1 Dormant Projects Company Details
11.10.2 Dormant Projects Business Overview
11.10.3 Dormant Projects Retinitis Pigmentosa (Retinitis) Introduction
11.10.4 Dormant Projects Revenue in Retinitis Pigmentosa (Retinitis) Business (2019-2024)
11.10.5 Dormant Projects Recent Developments
11.11 GenSight Biologics SA
11.11.1 GenSight Biologics SA Company Details
11.11.2 GenSight Biologics SA Business Overview
11.11.3 GenSight Biologics SA Retinitis Pigmentosa (Retinitis) Introduction
11.11.4 GenSight Biologics SA Revenue in Retinitis Pigmentosa (Retinitis) Business (2019-2024)
11.11.5 GenSight Biologics SA Recent Developments
11.12 Grupo Ferrer Internacional SA
11.12.1 Grupo Ferrer Internacional SA Company Details
11.12.2 Grupo Ferrer Internacional SA Business Overview
11.12.3 Grupo Ferrer Internacional SA Retinitis Pigmentosa (Retinitis) Introduction
11.12.4 Grupo Ferrer Internacional SA Revenue in Retinitis Pigmentosa (Retinitis) Business (2019-2024)
11.12.5 Grupo Ferrer Internacional SA Recent Developments
11.13 ID Pharma
11.13.1 ID Pharma Company Details
11.13.2 ID Pharma Business Overview
11.13.3 ID Pharma Retinitis Pigmentosa (Retinitis) Introduction
11.13.4 ID Pharma Revenue in Retinitis Pigmentosa (Retinitis) Business (2019-2024)
11.13.5 ID Pharma Recent Developments
11.14 InFlectis BioScience
11.14.1 InFlectis BioScience Company Details
11.14.2 InFlectis BioScience Business Overview
11.14.3 InFlectis BioScience Retinitis Pigmentosa (Retinitis) Introduction
11.14.4 InFlectis BioScience Revenue in Retinitis Pigmentosa (Retinitis) Business (2019-2024)
11.14.5 InFlectis BioScience Recent Developments
11.15 Ionis Pharmaceuticals
11.15.1 Ionis Pharmaceuticals Company Details
11.15.2 Ionis Pharmaceuticals Business Overview
11.15.3 Ionis Pharmaceuticals Retinitis Pigmentosa (Retinitis) Introduction
11.15.4 Ionis Pharmaceuticals Revenue in Retinitis Pigmentosa (Retinitis) Business (2019-2024)
11.15.5 Ionis Pharmaceuticals Recent Developments
11.16 Mimetogen Pharmaceuticals
11.16.1 Mimetogen Pharmaceuticals Company Details
11.16.2 Mimetogen Pharmaceuticals Business Overview
11.16.3 Mimetogen Pharmaceuticals Retinitis Pigmentosa (Retinitis) Introduction
11.16.4 Mimetogen Pharmaceuticals Revenue in Retinitis Pigmentosa (Retinitis) Business (2019-2024)
11.16.5 Mimetogen Pharmaceuticals Recent Developments
11.17 M's Science Corp
11.17.1 M's Science Corp Company Details
11.17.2 M's Science Corp Business Overview
11.17.3 M's Science Corp Retinitis Pigmentosa (Retinitis) Introduction
11.17.4 M's Science Corp Revenue in Retinitis Pigmentosa (Retinitis) Business (2019-2024)
11.17.5 M's Science Corp Recent Developments
11.18 Nanovector srl
11.18.1 Nanovector srl Company Details
11.18.2 Nanovector srl Business Overview
11.18.3 Nanovector srl Retinitis Pigmentosa (Retinitis) Introduction
11.18.4 Nanovector srl Revenue in Retinitis Pigmentosa (Retinitis) Business (2019-2024)
11.18.5 Nanovector srl Recent Developments
11.19 Novartis AG
11.19.1 Novartis AG Company Details
11.19.2 Novartis AG Business Overview
11.19.3 Novartis AG Retinitis Pigmentosa (Retinitis) Introduction
11.19.4 Novartis AG Revenue in Retinitis Pigmentosa (Retinitis) Business (2019-2024)
11.19.5 Novartis AG Recent Developments
11.20 Novelion Therapeutics
11.20.1 Novelion Therapeutics Company Details
11.20.2 Novelion Therapeutics Business Overview
11.20.3 Novelion Therapeutics Retinitis Pigmentosa (Retinitis) Introduction
11.20.4 Novelion Therapeutics Revenue in Retinitis Pigmentosa (Retinitis) Business (2019-2024)
11.20.5 Novelion Therapeutics Recent Developments
11.21 ProQR Therapeutics
11.21.1 ProQR Therapeutics Company Details
11.21.2 ProQR Therapeutics Business Overview
11.21.3 ProQR Therapeutics Retinitis Pigmentosa (Retinitis) Introduction
11.21.4 ProQR Therapeutics Revenue in Retinitis Pigmentosa (Retinitis) Business (2019-2024)
11.21.5 ProQR Therapeutics Recent Developments
11.22 ReNeuron Group Plc
11.22.1 ReNeuron Group Plc Company Details
11.22.2 ReNeuron Group Plc Business Overview
11.22.3 ReNeuron Group Plc Retinitis Pigmentosa (Retinitis) Introduction
11.22.4 ReNeuron Group Plc Revenue in Retinitis Pigmentosa (Retinitis) Business (2019-2024)
11.22.5 ReNeuron Group Plc Recent Developments
11.23 SanBio
11.23.1 SanBio Company Details
11.23.2 SanBio Business Overview
11.23.3 SanBio Retinitis Pigmentosa (Retinitis) Introduction
11.23.4 SanBio Revenue in Retinitis Pigmentosa (Retinitis) Business (2019-2024)
11.23.5 SanBio Recent Developments
11.24 Shire (Takeda Pharmaceutical)
11.24.1 Shire (Takeda Pharmaceutical) Company Details
11.24.2 Shire (Takeda Pharmaceutical) Business Overview
11.24.3 Shire (Takeda Pharmaceutical) Retinitis Pigmentosa (Retinitis) Introduction
11.24.4 Shire (Takeda Pharmaceutical) Revenue in Retinitis Pigmentosa (Retinitis) Business (2019-2024)
11.24.5 Shire (Takeda Pharmaceutical) Recent Developments
11.25 Spark Therapeutics
11.25.1 Spark Therapeutics Company Details
11.25.2 Spark Therapeutics Business Overview
11.25.3 Spark Therapeutics Retinitis Pigmentosa (Retinitis) Introduction
11.25.4 Spark Therapeutics Revenue in Retinitis Pigmentosa (Retinitis) Business (2019-2024)
11.25.5 Spark Therapeutics Recent Developments
11.26 Sun Pharma Advanced Research Company
11.26.1 Sun Pharma Advanced Research Company Company Details
11.26.2 Sun Pharma Advanced Research Company Business Overview
11.26.3 Sun Pharma Advanced Research Company Retinitis Pigmentosa (Retinitis) Introduction
11.26.4 Sun Pharma Advanced Research Company Revenue in Retinitis Pigmentosa (Retinitis) Business (2019-2024)
11.26.5 Sun Pharma Advanced Research Company Recent Developments
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Sanofi
Amgen
Amarantus Bioscience Holdings
Acucela
Applied Genetic Technologies Corp
Asklepios BioPharmaceutical
Astellas Pharma
Caladrius Biosciences
Dompe Farmaceutici SpA
Dormant Projects
GenSight Biologics SA
Grupo Ferrer Internacional SA
ID Pharma
InFlectis BioScience
Ionis Pharmaceuticals
Mimetogen Pharmaceuticals
M's Science Corp
Nanovector srl
Novartis AG
Novelion Therapeutics
ProQR Therapeutics
ReNeuron Group Plc
SanBio
Shire (Takeda Pharmaceutical)
Spark Therapeutics
Sun Pharma Advanced Research Company
听
听
*If Applicable.
